CAR-T manufacturing intensification: the next wave of CAR-T commercialization

Since the commercialization of the first CAR-T therapies, these revolutionary treatments have reshaped the landscape of cancer therapy, offering unprecedented hope to patients with hematologic malignancies. Here, a panel of industry and healthcare sector experts to discuss the critical intersection of commercialization strategies and manufacturing technology in advancing the next wave of CAR-T therapies to market. They explore the current industry status and the latest innovations that have the potential to optimize manufacturing processes for scale-up or scale-out, impacting cost of goods (CoGs) and manufacturing success to meet the growing demand and ensure broader patient access.

Please enter your email to access content Read now